Recombinant human interferon alpha-2a increases the antitumor activity of 5-fluorouracil on human colon carcinoma xenograft Co-4 without any change in 5-FU pharmacokinetics

S. Kase, T. Kubota, M. Watanabe, T. Furukawa, H. Tanino, T. H. Kuo, Y. Saikawa, T. Teramoto, M. Kitajima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We investigated the modulating effect of recombinant human interferon alpha-2a (IFN-α) on the antitumor activity of 5-fluorouracil (5-FU) against a human colon carcinoma xenograft (Co-4) in nude mice with reference to changes in the pharmacokinetic pattern of 5-FU. Mice bearing Co-4 received 5-FU ip at a dose of 90 mg/kg once with or without IFN-α, which was administered sc at a dose of 60.000 IU/mouse daily for 7 days before 5-FU treatment. When the area under the curve (AUC) and peak plasma concentration (Cmax) of 5-FU with or without IFN-α were measured as pharmacokinetic parameters, the pharmacokinetics of 5-FU was not changed by IFN-α administration. This result suggests that the modulating effect of IFN-α on 5-FU does not involve augmentation of 5-FU pharmacokinetic parameters.

Original languageEnglish
Pages (from-to)153-155
Number of pages3
JournalAnticancer research
Volume15
Issue number1
Publication statusPublished - 1995 Jan 1

Keywords

  • 5-fluorouracil
  • Human colon carcinoma
  • Interferon alpha

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Recombinant human interferon alpha-2a increases the antitumor activity of 5-fluorouracil on human colon carcinoma xenograft Co-4 without any change in 5-FU pharmacokinetics'. Together they form a unique fingerprint.

  • Cite this